• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Imagin Molecular Corporation Enters into Coronary Artery Disease Reversal and Prevention Centers Market

Posted on: Thursday, 23 February 2006, 09:01 CST

Imagin Molecular Corporation (OTCBB:IMGM) announced today plans to own, operate and administer out-patient coronary artery disease (CAD) reversal and prevention centers (medical diagnostic imaging and therapy centers) that utilizes PET and PET/CT scanning equipment. Imagin's strategy and focus is dedicated to offering a research proven, non-surgical CAD reversal program guided by non-invasive imaging. Imagin possesses a bioinformatics, evidence-based, solution for the cost containment of CAD detection and treatment based on PET diagnostics as a primary modality. Through the Company's association with Positron Corporation, Imagin is able deliver a less expensive PET and PET/CT that eliminates a major barrier to entry for the CAD reversal and prevention centers. This full-solution will facilitate widespread clinical acceptance.

Imagin Nuclear Partners, Imagin Molecular Corporation's wholly owned subsidiary, has targeted 20 key markets in which they will joint venture with an existing cardiology group or open a free-standing center around an active cholesterol management program. Imagin Nuclear Partners has identified the CAD reversal and prevention center market at over 7,000 community hospitals and private imaging partners that would benefit from Imagin Nuclear Partner's methodology and solution. Currently Imagin Nuclear Partners is in negotiations with five imaging centers to form such joint ventures.

Joseph Oliverio, CEO of Imagin Molecular Corporation, states, "I am excited to duplicate the proven model of Niagara Falls Memorial Medical Center which demonstrated the ability of Positron Emission Tomography to provide the necessary competitive advantage solution of detecting and guiding the management of coronary disease differently than equal and larger sized hospital competition. I believe that other markets will embrace our proven cost savings methodology which has been shown to also improve patient outcomes."

Mr. Oliverio also serves as President of Positron Corporation, a leading manufacture of PET devices. Previously, Mr. Oliverio was Chief Operating Officer of Heart Center of Niagara, a private PET practice owned by Michael E. Merhige, M.D, operating within Niagara Falls Memorial Medical Center. Heart Center of Niagara is one of the countries most successful coronary disease reversal and prevention centers, and will be Imagin Nuclear Partners model center.

About Imagin Molecular Corporation:

Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Nuclear Partners, a wholly owned subsidiary of Imagin Molecular Corporation, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment. Imagin Nuclear Partners specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. Cipher Multimedia will develop marketing campaigns that will assist Imagin, Positron Corporation and other companies market their products and will continue to provide publishers a distribution solution for digital content.

About Positron Corporation:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; The Heart Center of Niagara in Niagara Falls, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at http://www.positron.com/.

For further information please contact Joe Oliverio at Imagin Molecular Corporation at 630 371 5583

Source: Business Wire

More News in this Category